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T
he role of the gut and gut-associated lymphoid
tissue in the development of type 1 diabetes has
come into the research focus over the last 20
years. Accumulated evidence suggests that the
gut is involved in the pathogenesis of this immune-medi-
ated disease, and there seem to be several mechanisms by
which such an effect may be mediated (1). Decreased
microbial diversity in the gut, increased intestinal perme-
ability, local inﬂammation in the gastrointestinal tract, and
abnormal mucosal immune responses all may contribute
to the appearance of -cell autoimmunity and further
progression to overt type 1 diabetes. The intestinal mu-
cosa comprises the largest surface area in the body, and
the gut-associated lymphoid tissue represents the most
extensive immune organ. The gut plays accordingly a
crucial role in the interaction between the host and the
environment. Given that type 1 diabetes is the unfortunate
consequence of the combined effects of the individual
genetic setup and exogenous and host-related factors, it is
not surprising that the gut might be involved in the process
leading to clinical disease.
In this issue of Diabetes, Mojibian et al. (2) report that
approximately half of the patients with type 1 diabetes,
whom they studied, had a proliferative T-cell response to
dietary wheat polypeptides and that the cytokine proﬁle of
the response was predominantly proinﬂammatory. A pos-
itive T-cell response to wheat polypeptides was associated
with the HLA DR4-DQ8 haplotype but surprisingly not with
the HLA DR3-DQ2 haplotype, which confers strong sus-
ceptibility to celiac disease. The investigators interpret
their observations as reﬂecting a diabetes-related inﬂam-
matory state in the gut immune system associated with
defective oral tolerance and a possible gut barrier dysfunc-
tion (Fig. 1). Accordingly, these observations add to the
accumulating concept that the gut is an active player in the
diabetes disease process.
The ﬁndings of Mojibian et al. also raise a series of
questions. Are the observed T-cell responses to wheat
polypeptides present in subjects with preclinical type 1
diabetes? The mean duration of clinical diabetes was 11.2
years in the 42 patients included in the present study.
Accordingly, one cannot exclude the possibility that the
observed T-cell responses to wheat polypeptides may
reﬂect hyperglycemia-induced changes in the intestinal
barrier function. No data were provided on glycemic
control in the patients studied nor any comparison on the
metabolic control between the patients with a positive
T-cell response and those lacking such a response. It
would be important to assess T-cell responses to wheat
polypeptides in subjects with preclinical type 1 diabetes in
order to exclude the possibility that the responses are
secondary to the disease condition.
Another issue is why T-cell responses to wheat polypep-
tides could be seen in only approximately half of the
patients. Would that indicate that the other half have
developed clinical type 1 diabetes without any intestinal
involvement? It is intriguing that other studies focusing on
various aspects of the gastrointestinal system have also
reported abnormalities in 20–50% of the patients ana-
lyzed. Westerholm-Ormio et al. (3) found enhanced ex-
pression of HLA-DR and -DP, intracellular adhesion
molecule-1, 47-integrin, interleukin (IL)-4, IL-1, and
-interferon in small intestinal biopsy samples from 20–
30% of children with type 1 diabetes, and they interpreted
these ﬁndings as signs of intestinal inﬂammation. Auric-
chio et al. (4) observed higher density of intraepithelial
CD3
 and of / T-cells and lamina propria CD25
 T-cells
reﬂecting the activation of intestinal immunity in 50% of
the patients with type 1 diabetes. Sapone et al. (5) mea-
sured elevated serum levels of zonulin, implicated as one
of the tight junction proteins, in 42% of patients affected by
type 1 diabetes. Taken together, these observations imply
that only a proportion of patients with type 1 diabetes do
have signs of intestinal inﬂammation and increased
permeability.
The study by Mojibian et al. raises the possibility that
wheat could be the driving dietary antigen in two autoim-
mune diseases, i.e., celiac disease and type 1 diabetes. It is
well established that celiac disease is induced, in geneti-
cally susceptible individuals, by the ingestion of gluten, the
major storage protein of wheat and similar grains (6).
Gliadin is the alcohol-soluble fraction of gluten that con-
tains most of the toxic components. Undigested molecules
of gliadin are resistant to degradation by gastric, pancre-
atic, and intestinal proteases in the human intestine and
accordingly remain in the intestinal lumen after gluten
ingestion (7). These peptides pass through the gut epithe-
lial barrier of the intestine, possibly during enteral infec-
tions or when there is an increase in intestinal
permeability for some other reason, and interact with
antigen-presenting cells in the lamina propria. In patients
with celiac disease, immune responses to gliadin fractions
promote an inﬂammatory reaction, primarily in the upper
small intestine, characterized by inﬁltration of the lamina
propria and the epithelium with chronic inﬂammatory
cells. Approximately 85–90% of the patients with celiac
disease carry the HLA DR3-DQ2 haplotype, and a majority
of the remaining patients carry the HLA DR4-DQ8 haplo-
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types seems to be associated with a decreased risk for
celiac disease.
According to the present data, wheat polypeptides gen-
erated by chymotrypsin treatment of gluten resulted in
vitro in a proliferative T-cell response in 42% of the
patients analyzed. A majority of the responders were HLA
DR3/DR4 heterozygous, whereas only one carried the HLA
DR3-DQ2 haplotype in combination with a non–HLA DR4-
DQ8 haplotype—the most common celiac disease–associ-
ated genotype. The response was characterized by a
proinﬂammatory cytokine response dominated by in-
creased secretion of -interferon, tumor necrosis factor,
and IL-17A. The secretion of IL-4 and IL-6 was also
increased; however, the investigators argue that the IL-6
was secreted most likely by non–T-cells given that the
secretion was not inhibited by anti-DR antibodies. Taken
together, these observations suggest that the described
T-cell response differs from that characteristic of celiac
disease. A critical issue is whether the wheat polypeptides
tested here are naturally occurring antigens in the intesti-
nal lumen. In addition to the difference observed in the
HLA association, there are also other differences between
the gut inﬂammation seen in patients with type 1 diabetes
compared with the inﬂammation characteristics of pa-
tients with celiac disease. Overall, the inﬂammatory state
seems to be a more active process in patients with celiac
disease (3). One study focused on the density and function
of T-cells in jejunal mucosa expressing the transcription
factor Foxp3 perceived as a marker of regulatory T-cells.
In children with type 1 diabetes, the densities of Foxp3-
positive cells were low and did not show activation of
Foxp3 transcripts (8). This was in contrast to celiac
disease, where mucosal inﬂammation involving Foxp3
expression was noted. The absence of intestinal Foxp3
activation in type 1 diabetes provides a strong rationale for
further investigation regarding whether impaired regula-
tory mechanisms could explain the subclinical intestinal
immune activation and altered responses to dietary anti-
gens seen in patients with type 1 diabetes. Such a mecha-
nism may also be behind the proliferative T-cell response
to wheat polypeptides and the associated proinﬂammatory
cytokine response reported by Mojibian et al.
Although additional work is needed to verify that the
observed phenomena are primary and present already in
subjects with preclinical type 1 diabetes, these observa-
tions add to the growing evidence that dietary compo-
nents may be involved in the disease process resulting
in clinical type 1 diabetes by intestinal pathways. These
may include effects on gut microbiota, intestinal perme-
ability, and gut immune function as recently discussed
by Vaarala et al. (1).
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FIG. 1. Proposed pathway for a wheat-induced intestinal inﬂammation
in patients with type 1 diabetes. Wheat polypeptides pass through the
apical junction system from the gut lumen to the mucosa and are
presented to T-cells by dendritic cells (DCs) in an HLA DR-restricted
manner. The activated T-cells stimulate T-helper type 1 (Th1) cells to
produce -interferon (INF-) and tumor necrosis factor (TNF), Th2
cells to secrete IL-4, and Th17 cells to secrete IL-17A. This cytokine
cascade results in local inﬂammation.
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